Retatrutide is a new drug for weight loss and improving overall health. It works by activating three different hormones in the body that control hunger, appetite, and metabolism.
Think of it as a triple-action medication that:
- Helps you feel full faster
- Reduces your appetite
- Boosts your metabolism
By targeting these three areas simultaneously, Retatrutide aims to help people lose weight more effectively than previous medications.
Benefits of Retatrutide
Retatrutide, an innovative triple agonist medication targeting GIP, GLP-1, and glucagon receptors, offers several significant benefits:
Substantial Weight Loss
- Clinical trials showed remarkable weight reduction of up to 24.2% after 48 weeks with the highest dose.
- Nearly two-thirds of participants lost 20% or more of their body weight, and one-quarter lost over 30%.
Metabolic Improvements
- Significant reductions in HbA1c levels and improved insulin sensitivity.
- 72% of participants with prediabetes reverted to normoglycemia by the end of a recent trial.
Cardiovascular Benefits
- Improved lipid profiles with reductions in non-HDL-C by up to 26.9% and apoB by up to 24.2% at 48 weeks.
- Reduced triglycerides and apoC-III levels by up to 40.6% and 38.0%, respectively.
- Decreased number of atherogenic small LDL particles.
Liver Health
- Resolved steatosis in >85% of subjects with metabolic dysfunction-associated steatotic liver disease.
- 93% of patients taking the higher dose lost enough liver fat to drop below 5% by week 48.
Quality of Life Improvements
- Enhanced health-related quality of life compared to placebo.
- Improved scores of perceived hunger and disinhibition.
Muscle Preservation
Unlike some weight loss medications, Retatrutide helps preserve lean muscle mass while effectively targeting fat loss.
Clients should consult with one of our providers to determine if it might be suitable for them. The medication is administered as a once-weekly subcutaneous injection, with dosage typically starting low and gradually increasing to minimize side effects.
